# EDGAR Filing Document

**Accession Number:** 0000714256
**File Stem:** 0001493152-23-005752
**Filing Date:** 2023-2
**Character Count:** 12839
**Document Hash:** 297afaf97ffb3734e7f3b79409fac66d
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-23-005752.hdr.sgml**: 20230222

**ACCESSION NUMBER**: 0001493152-23-005752

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 14

**CONFORMED PERIOD OF REPORT**: 20230222

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20230222

**DATE AS OF CHANGE**: 20230222

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Sanara MedTech Inc.
- **CENTRAL INDEX KEY:** 0000714256
- **STANDARD INDUSTRIAL CLASSIFICATION:** ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842]
- **IRS NUMBER:** 592220004
- **STATE OF INCORPORATION:** TX
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-39678
- **FILM NUMBER:** 23650753

**BUSINESS ADDRESS:**
- **STREET 1:** 1200 SUMMIT AVE
- **STREET 2:** SUITE 414
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76102
- **BUSINESS PHONE:** 817-529-2300

**MAIL ADDRESS:**
- **STREET 1:** 1200 SUMMIT AVE
- **STREET 2:** SUITE 414
- **CITY:** FORT WORTH
- **STATE:** TX
- **ZIP:** 76102

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** WOUND MANAGEMENT TECHNOLOGIES, INC.
- **DATE OF NAME CHANGE:** 20080611

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** MB SOFTWARE CORP
- **DATE OF NAME CHANGE:** 19960805

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** INAV TRAVEL CORPORATION
- **DATE OF NAME CHANGE:** 19920703

?xml version="1.0" encoding="utf-8"?

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, D.C. 20549**

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **February 22, 2023**

---

| |
|:---|
| **SANARA MEDTECH INC.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | | |
|:---|:---|:---|
| **Texas** | **001-39678** | **59-2219994** |
| (State or other jurisdiction of | (Commission | (IRS Employer |
| incorporation) | File Number) | Identification No.) |

---

---

| | |
|:---|:---|
| **1200 Summit Avenue, Suite 414**<br> **Fort Worth, Texas** | **76102** |
| (Address of principal executive offices) | (Zip Code) |

---

Registrant's telephone number, including area code: **(817) 529-2300**

(Former name or former address, if changed since last report)

**Not Applicable**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) 

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) 

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) 

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **Title of each class** | **Trading Symbol(s)** | **Name of each exchange on which registered** |
| Common Stock, $0.001 par value | SMTI | The Nasdaq Capital Market |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

---

| | |
|:---|:---|
| Emerging growth company | **☐** |

---

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. **☐**

 ****

 ****

---

| | |
|:---|:---|
| **Item 2.02** | **Results of Operations and Financial Condition.** |

---

On February 22, 2023, Sanara MedTech Inc. (the "Company") issued a press release announcing certain unaudited preliminary financial results for the fourth quarter and full year 2022. A copy of the Company's press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated by reference herein.

The information in this Current Report on Form 8-K, including Exhibit 99.1 furnished hereto, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth in such filing.

---

| | |
|:---|:---|
| **Item 9.01** | **Financial Statements and Exhibits.** |

---

**(d) Exhibits**

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | [Press Release issued February 22, 2023 (furnished pursuant to Item 2.02).](ex99-1.htm) |
| 104 | Cover Page Interactive Data File (embedded within the Inline XBRL document). |

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | | | |
|:---|:---|:---|:---|
| Date: | February 22, 2023 |  |  |
|  |  | **Sanara MedTech Inc**. | **Sanara MedTech Inc**. |
|  |  | By: | */s/ Michael D. McNeil* |
|  |  | Name: | Michael D. McNeil |
|  |  | Title: | Chief Financial Officer |

---

## Exhibit 99.1

**Exhibit 99.1**

![](ex99-1_001.jpg)

**Sanara MedTech Inc. Announces Unaudited Preliminary Results for the Fourth Quarter and Full Year 2022**

**FORT WORTH, TX / GLOBENEWSWIRE / February 22, 2023 / Sanara MedTech Inc**. Based in Fort Worth, Texas, Sanara MedTech Inc. ("Sanara," the "Company," "we," "our" or "us") (NASDAQ: SMTI), a medical technology company focused on developing and commercializing transformative technologies to improve clinical outcomes and reduce healthcare expenditures in the surgical, chronic wound and skin care markets, announced today certain unaudited preliminary results for the fourth quarter and full-year 2022.

**Selected Fourth Quarter and Full-Year 2022 Preliminary Results (Unaudited)**

● Net revenue of approximately $15.3 million for the three months ended December 31, 2022, compared to net revenue of $7.0 million for the three months ended December 31, 2021, which would result in a record net revenue quarter and represent a 119% increase from the prior year period.

● Net revenue of approximately $45.8 million for the year ended December 31, 2022, compared to net revenue of $24.1 million for the year ended December 31, 2021, representing a 90% increase from the prior year. The higher net revenues in 2022 were primarily due to increased sales of surgical products as a result of our increased market penetration and expanded product offering, our continuing strategy implementation of expanding our sales force and independent distribution network in both new and existing U.S. markets, as well as additional revenues from the Scendia Biologics, LLC ("Scendia") acquisition.

● Operating loss is expected to be between $2.0 million and $3.5 million for the three months ended December 31, 2022, compared to an operating loss of $3.4 million for the three months ended December 31, 2021.

● Operating loss is expected to be between $11.0 million and $12.5 million for the year ended December 31, 2022, compared to operating loss of $7.4 million for the year ended December 31, 2021. The higher operating loss in 2022 was primarily due to higher expenses related to research and development, higher non-cash amortization expense related to intangible assets acquired as part of our acquisitions of Precision Healing Inc. and Scendia and higher costs related to sales force expansion and operational support.

● Cash and cash equivalents were approximately $9.0 million as of December 31, 2022.

● As a result of the dissolution of Sanara Pulsar, LLC ("Sanara Pulsar"), an entity that was majority-owned by a wholly owned subsidiary of Sanara, we recorded a non-cash loss on disposal of investment in the fourth quarter of 2022 totaling approximately $1.0 million. The loss on disposal of investment will be included in "Other expense" in Sanara's Statement of Operations for the year ended December 31, 2022. At the time of the formation of Sanara Pulsar, Sanara Pulsar and Wound Care Solutions, Limited ("WCS") entered into a supply agreement whereby Sanara Pulsar became the exclusive distributor in the United States of certain wound care products, including the Sanara Pulsar II AWI Wound Debridement System, that utilized intellectual property developed and owned by WCS (collectively, the "Pulsar Products"). When we formed Sanara Pulsar, we believed the Pulsar Products would provide clinicians with a novel debridement solution. We also believed the Pulsar Products would receive an expanded reimbursement code for use by all clinician types. Ultimately, we did not receive an additional reimbursement code, which limited the adoption of the Pulsar Products.

Zach Fleming, Sanara's CEO, stated, "In 2022, Sanara saw significant net revenue growth as a result of increased sales of our surgical products including those we market through our acquisition of Scendia and the products we license from Cook Biotech Inc. The efficacy of our CellerateRX<sup>®</sup> Surgical line of products and our ability to offer an expanded portfolio of products were both key drivers of our success in 2022 and we believe they will continue to help drive growth in 2023."

Our independent registered public accounting firm has not completed its procedures with respect to the preliminary financial information or its audit of our financial statements for the year ended December 31, 2022. Our actual results may differ from these estimates as a result of the completion of our audit and other developments that may arise between now and the time our financial results for the fourth quarter and year are finalized.

**About Sanara MedTech Inc.**

With a focus on improving patient outcomes through evidence-based healing solutions, Sanara MedTech Inc. markets, distributes and develops surgical, wound and skincare products for use by physicians and clinicians in hospitals, clinics and all post-acute care settings and offers wound care and dermatology virtual consultation services via telemedicine. Sanara's products are primarily sold in the North American advanced wound care and surgical tissue repair markets. Sanara markets and distributes CellerateRX<sup>®</sup> Surgical Activated Collagen<sup>®</sup>, FORTIFY TRG<sup>®</sup> Tissue Repair Graft and FORTIFY FLOWABLE<sup>®</sup> Extracellular Matrix as well as a portfolio of advanced biologic products focusing on AMPLIFY<sup>™</sup> Verified Inductive Bone Matrix, ALLOCYTE<sup>™</sup> Advanced Cellular Bone Matrix, BiFORM<sup>®</sup> Bioactive Moldable Matrix and TEXAGEN<sup>®</sup> Amniotic Membrane Allograft to the surgical market. In addition, the following products are sold in the wound care market: BIAKŌS<sup>™</sup> Antimicrobial Skin and Wound Cleanser, BIAKŌS<sup>™</sup> Antimicrobial Wound Gel, BIAKŌS<sup>™</sup> Antimicrobial Skin and Wound Irrigation Solution and HYCOL<sup>®</sup> Hydrolyzed Collagen. Sanara's pipeline also contains potentially transformative product candidates for mitigation of opportunistic pathogens and biofilm, wound re-epithelialization and closure, necrotic tissue debridement, and cell compatible substrates. The Company believes it has the ability to drive its pipeline from concept to preclinical and clinical development while meeting quality and regulatory requirements. Sanara is constantly seeking long-term strategic partnerships with a focus on products that improve outcomes at a lower overall cost. In addition, Sanara is actively seeking to expand within its six focus areas of wound and skin care for the acute, post-acute, and surgical markets. The focus areas are debridement, biofilm removal, hydrolyzed collagen, advanced biologics, negative pressure wound therapy products, and the oxygen delivery system segment of the wound and skincare market.

**Information about Forward-Looking Statements**

All forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to revise any of these statements to reflect the future circumstances or the occurrence of unanticipated events, except as required by applicable securities laws.

**Investor Contact:**

Callon Nichols, Director of Investor Relations

713-826-0524

<u>CNichols@sanaramedtech.com</u>

**SOURCE: Sanara MedTech Inc**.